FibroBiologics(FBLG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

FBLG FibroBiologics

盘前交易 11-12 05:53:27 EST

0.9958

+0.0719

+7.78%

最高1.04	最低0.9200	成交量5.44万
今开0.9400	昨收0.9239	日振幅12.99%
总市值663.02万	流通市值552.13万	总股本665.82万
成交额5.27万	换手率0.98%	流通股本554.46万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":0.9958,"timestamp":1794430800000,"preClose":0.9239,"halted":0,"volume":54376,"delay":0,"changeRate":0.0778222751380019,"floatShares":5544609,"shares":6658200,"eps":-4.765638,"marketStatus":"盘前交易","change":0.0719,"latestTime":"11-12 05:53:27 EST","open":0.94,"high":1.04,"low":0.92,"amount":52722.78254656,"amplitude":0.129884,"askPrice":1.13,"askSize":100,"bidPrice":0.824,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.765638,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794493800000},"marketStatusCode":1,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":0.9958,"postHourTrading":{"tag":"盘后","latestPrice":0.9958,"preClose":0.9958,"latestTime":"19:30 EST","volume":51,"amount":51.3435,"timestamp":1794443400990,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8661743461730235},"requestUrl":"/m/hq/s/FBLG","defaultTab":"news","newsList":[{"id":"1140980227","title":"FibroBiologics宣布获得美国新专利：利用成纤维细胞条件培养基治疗椎间盘退行性疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1140980227","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140980227?lang=zh_cn&edition=full","pubTime":"2026-09-01 20:31","pubTimestamp":1788265870,"startTime":"0","endTime":"0","summary":"FibroBiologics今日宣告，其一项针对椎间盘退行性疾病治疗的新美国专利已正式获批。此项专利聚焦于成纤维细胞条件培养基的应用，为该疾病的治疗开辟了全新路径。这标志着公司在再生医学领域的持续深耕又迈出了坚实一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199334671","title":"Fibrobiologics发布第三批Cywc628药物产品，用于1/2期糖尿病足溃疡临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1199334671","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199334671?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:34","pubTimestamp":1787834050,"startTime":"0","endTime":"0","summary":"Fibrobiologics公司宣布，已成功生产并发布第三批Cywc628药物产品，该产品将用于其正在进行的1/2期糖尿病足溃疡临床试验。这一里程碑式的进展，标志着该公司在推进这一潜在治疗方案的道路上又迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172853300","title":"FibroBiologics获美国专利：成纤维细胞可增强移植胰岛细胞存活与功能","url":"https://stock-news.laohu8.com/highlight/detail?id=1172853300","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172853300?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:32","pubTimestamp":1786451534,"startTime":"0","endTime":"0","summary":"FibroBiologics（FBLG）近日宣布，已获得一项美国专利授权。该专利覆盖了利用成纤维细胞来增强移植后胰岛素生产胰岛细胞的存活率与功能。这一技术突破，有望为糖尿病细胞疗法带来新的助力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181092968","title":"FibroBiologics发布2026年第二季度财报：主导伤口护理候选药物临床试验稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1181092968","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181092968?lang=zh_cn&edition=full","pubTime":"2026-08-01 05:35","pubTimestamp":1785533709,"startTime":"0","endTime":"0","summary":"FibroBiologics（股票代码：FBLG）近日披露了其2026年第二季度的财务业绩。与此同时，该公司在评估其核心伤口护理候选药物的临床试验方面，也取得了显著进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157352361","title":"FibroBiologics提交SEC文件：注册出售股东至多1253万股普通股转售","url":"https://stock-news.laohu8.com/highlight/detail?id=1157352361","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157352361?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:07","pubTimestamp":1783678031,"startTime":"0","endTime":"0","summary":"FibroBiologics已向美国证券交易委员会提交文件，为其部分出售股东注册了高达1253万股普通股的转售资格。此举意味着，持有这些已注册股份的股东未来可在公开市场出售这些股票，而公司本身不会从此次转售中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128222368","title":"FibroBiologics完成第三批Cywc628药物生产，用于糖尿病足溃疡1/2期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1128222368","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128222368?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:35","pubTimestamp":1783427707,"startTime":"0","endTime":"0","summary":"FibroBiologics宣布，已完成用于糖尿病足溃疡1/2期临床试验的第三批Cywc628药物产品的生产工作。该进展标志着公司针对这一适应症的临床开发计划取得了关键一步，为后续的试验推进提供了必要的材料保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150619750","title":"FibroBiologics宣布完成最高900万美元按市价定价的私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1150619750","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150619750?lang=zh_cn&edition=full","pubTime":"2026-06-30 04:02","pubTimestamp":1782763335,"startTime":"0","endTime":"0","summary":"FibroBiologics公司宣布，其依据纳斯达克规则按市价定价的私募配售已正式完成，此次融资规模最高可达900万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115715028","title":"FibroBiologics推进针对糖尿病足溃疡的Ciwc628药物1/2期临床试验患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1115715028","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115715028?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:31","pubTimestamp":1781613092,"startTime":"0","endTime":"0","summary":"FibroBiologics公司宣布，其用于治疗糖尿病足溃疡的研究性药物Ciwc628的1/2期临床试验已取得进展，进入患者给药阶段。这一步骤标志着该疗法在临床开发路径上的重要推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156476620","title":"FibroBiologics宣布首批患者接受Cywc628治疗糖尿病足溃疡的1/2期临床试验给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1156476620","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156476620?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:02","pubTimestamp":1780484567,"startTime":"0","endTime":"0","summary":"FibroBiologics宣布，其用于治疗糖尿病足溃疡的在研药物Cywc628，已在1/2期临床试验中为首批患者完成给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517943352","title":"Fibrobiologics, Inc.盘中异动 股价大涨5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943352","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517943352?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:35","pubTimestamp":1741185301,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时35分，Fibrobiologics, Inc.股票出现波动，股价快速上涨5.31%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.58%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223501a260c8a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223501a260c8a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517909607","title":"D. Boral Capital：维持FibroBiologics(FBLG.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517909607","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517909607?lang=zh_cn&edition=full","pubTime":"2025-03-05 02:11","pubTimestamp":1741111897,"startTime":"0","endTime":"0","summary":"D. Boral Capital：维持FibroBiologics(FBLG.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至16.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05021148524222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385335","title":"D. Boral Capital：维持FibroBiologics(FBLG.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385335","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385335?lang=zh_cn&edition=full","pubTime":"2025-02-28 01:55","pubTimestamp":1740678901,"startTime":"0","endTime":"0","summary":"D. Boral Capital：维持FibroBiologics(FBLG.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至16.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28015548441800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385824","title":"Fibrobiologics, Inc.盘中异动 早盘急速跳水5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385824?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:33","pubTimestamp":1740666812,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时33分，Fibrobiologics, Inc.股票出现异动，股价快速跳水5.26%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272233329632b140&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272233329632b140&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514071013","title":"Fibrobiologics, Inc.盘中异动 早盘股价大跌5.61%报1.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514071013","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514071013?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:18","pubTimestamp":1740496681,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时18分，Fibrobiologics, Inc.股票出现波动，股价大幅下挫5.61%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231802abdc89f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231802abdc89f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513227507","title":"Fibrobiologics, Inc.盘中异动 早盘股价大涨5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513227507","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513227507?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:31","pubTimestamp":1740407485,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时31分，Fibrobiologics, Inc.股票出现波动，股价大幅上涨5.78%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242231259890f570&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242231259890f570&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511696499","title":"Fibrobiologics, Inc.盘中异动 早盘股价大跌6.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511696499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511696499?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:41","pubTimestamp":1739544067,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时41分，Fibrobiologics, Inc.股票出现异动，股价大幅下挫6.20%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224107abcf08d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224107abcf08d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511252675","title":"Fibrobiologics, Inc.盘中异动 股价大跌9.83%报1.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511252675","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511252675?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:31","pubTimestamp":1739457099,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时31分，Fibrobiologics, Inc.股票出现波动，股价急速下挫9.83%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021322313998842b92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021322313998842b92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509441207","title":"Fibrobiologics, Inc.盘中异动 急速上涨10.62%报1.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509441207","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509441207?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:31","pubTimestamp":1738938666,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日22时31分，Fibrobiologics, Inc.股票出现波动，股价快速拉升10.62%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223106a23d22da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223106a23d22da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509277122","title":"Fibrobiologics, Inc.盘中异动 早盘股价大跌5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509277122","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509277122?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:59","pubTimestamp":1738853980,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时59分，Fibrobiologics, Inc.股票出现异动，股价快速下跌5.76%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.18%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206225941961a1dc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206225941961a1dc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507213966","title":"Fibrobiologics, Inc.盘中异动 早盘股价大涨11.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507213966","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507213966?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:32","pubTimestamp":1738247546,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时32分，Fibrobiologics, Inc.股票出现异动，股价急速上涨11.54%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223226a234554d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223226a234554d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fibrobiologics.com","stockEarnings":[{"period":"1week","weight":0.0282},{"period":"1month","weight":-0.0042},{"period":"3month","weight":-0.1341},{"period":"6month","weight":-0.0516},{"period":"1year","weight":-0.8525},{"period":"ytd","weight":-0.7786}],"compareEarnings":[{"period":"1week","weight":-0.0091},{"period":"1month","weight":-0.0235},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.0279},{"period":"1year","weight":0.1125},{"period":"ytd","weight":0.1142}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"FibroBiologics, Inc.最初于2021年4月8日根据德克萨斯州法律成立为有限责任公司，然后于2021年12月14日转变为特拉华州公司。FibroBiologics是一家早期细胞治疗公司，总部位于德克萨斯州休斯顿，开发利用成纤维细胞治疗慢性疾病的创新疗法。该公司的主要重点是启动和推进与成纤维细胞治疗退行性椎间盘疾病、多发性硬化症、癌症、伤口愈合和其他疾病相关的临床前研究和临床阶段FDA试验。","exchange":"NASDAQ","name":"FibroBiologics","nameEN":"FibroBiologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FibroBiologics(FBLG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供FibroBiologics(FBLG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"FibroBiologics,FBLG,FibroBiologics股票,FibroBiologics股票老虎,FibroBiologics股票老虎国际,FibroBiologics行情,FibroBiologics股票行情,FibroBiologics股价,FibroBiologics股市,FibroBiologics股票价格,FibroBiologics股票交易,FibroBiologics股票购买,FibroBiologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FibroBiologics(FBLG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供FibroBiologics(FBLG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}